GR2303

· Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GR2303, covering 2025-09-30 to 2025-09-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult [Phase 1]